ライフサイエンスコーパス: neuralgia

1 lodynia in this animal model of postherpetic neuralgia.

2 end point was the incidence of postherpetic neuralgia.

3 the unique clinical features of postherpetic neuralgia.

4 lt from the surgical treatment of trigeminal neuralgia.

5 nto the potential mechanisms of postherpetic neuralgia.

6 multiple sclerosis patients with trigeminal neuralgia.

7 r, and had an uncomplicated recovery without neuralgia.

8 t at risk of prolonged pain and postherpetic neuralgia.

9 y little pain, and there was no postherpetic neuralgia.

10 and account for the development of herpetic neuralgia.

11 nt of chickenpox, shingles, and postherpetic neuralgia.

12 l nerve for medically intractable trigeminal neuralgia.

13 nderlie pain in this kindred with trigeminal neuralgia.

14 erpes zoster but higher against postherpetic neuralgia.

15 ful air injection, none reported intercostal neuralgia.

16 imes demonstrating "pain without lesions" or neuralgia.

17 graine, tension-type headache, and occipital neuralgia.

18 select patients with migraine and occipital neuralgia.

19 ccount for the development of acute herpetic neuralgia.

20 y a critical role in the genesis of herpetic neuralgia.

21 erpes zoster and 70-88% against postherpetic neuralgia.

22 king in patients with presumed genitofemoral neuralgia.

23 effective for the diagnosis of genitofemoral neuralgia.

24 of Carbamazepine in treatment of Trigeminal Neuralgia.

25 er, which may be complicated by postherpetic neuralgia.

26 ndrome, Achilles tendinitis and medial nerve neuralgia.

27 shown striking similarities with trigeminal neuralgia.

28 gical concept of SUNCT, SUNA, and trigeminal neuralgia.

29 ical basis between SUNCT/SUNA and trigeminal neuralgia.

30 tial of EMA401 in patients with postherpetic neuralgia.

31 uritis with classical symptoms of peripheral neuralgia.

32 , which is often complicated by postherpetic neuralgia.

33 events such as xerophthalmia and trigeminal neuralgia.

34 or definitive management of chronic inguinal neuralgia.

35 thophysiology of pre- and typical trigeminal neuralgia.

36 d HZ severity and occurrence of postherpetic neuralgia.

37 d can be further complicated by postherpetic neuralgia.

38 th reduced HZ severity and less postherpetic neuralgia.

39 ed pain relief in patients with postherpetic neuralgia.

40 dults against herpes zoster and postherpetic neuralgia.

41 ed noninvasively in patients with trigeminal neuralgia.

42 r incidence, and probability of postherpetic neuralgia.

43 ive pain score in patients with postherpetic neuralgia.

44 complaints following surgery for trigeminal neuralgia.

45 ions of the surgical treatment of trigeminal neuralgia.

46 o 0.67 [0.61-0.74]) and 38% for postherpetic neuralgia (0.62 [0.50-0.79]).

47 NS infections, 12 (CI: 5, 13); post-herpetic neuralgia, 11 (CI: 6, 17); and major neurological injuri

48 bo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among plac

49 ster cases, 4982 (7%) developed postherpetic neuralgia, 4439 (6%) had herpes zoster ophthalmicus, and

50 oster, 62% (59% to 65%) against postherpetic neuralgia, 45% (40% to 49%) against herpes zoster ophtha

51 ous malformations (1089 [22.2%]), trigeminal neuralgia (565 [11.5%]), pituitary adenomas (641 [13.1%]

52 rospinal fluid from patients with trigeminal neuralgia accumulates reactive oxygen species, several o

53 ay contribute to the pathogenesis of corneal neuralgia after refractive surgery.

54 ts with and 16 subjects without postherpetic neuralgia after unilateral shingles.

55 ster and 3300 fewer episodes of postherpetic neuralgia among 5.5 million eligible individuals in the

56 orbidity from herpes zoster and postherpetic neuralgia among older adults.

57 y, or both of herpes zoster and postherpetic neuralgia among older adults.

58 also reported that HSV-1 causes postherpetic neuralgia and chronic occipital neuralgia in humans.

59 In postherpetic neuralgia and complex regional pain syndrome, for exampl

60 urther insight into the causes of trigeminal neuralgia and its pathophysiology.

61 ses of chronic pruritus include postherpetic neuralgia and notalgia paresthetica and are typically du

62 ms involved in the genesis of acute herpetic neuralgia and open new avenues for its control.

63 ultations for herpes zoster and postherpetic neuralgia, and aggregated these data to estimate vaccine

64 the neuro-ophthalmic features of trigeminal neuralgia, and detail the neuro-ophthalmic side effects

65 Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limi

66 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ,

67 often confused with migraine and trigeminal neuralgia, and secondary causes may be overlooked.

68 atio [aOR], 31.50), hemiplegia (aOR, 28.48), neuralgia (aOR, 4.81), optic atrophy (aOR, 3.74), paraly

69 ith autonomic symptoms (SUNA) and trigeminal neuralgia are considered different disorders, thus group

70 hysiological mechanisms involved in herpetic neuralgia are not totally elucidated.

71 is associated with shingles and postherpetic neuralgia, as well as with severe neurologic complicatio

72 at persistent RSD/CRPS-I is a post-traumatic neuralgia associated with distal degeneration of small-d

73 complications, namely incisional hernias and neuralgia at the trocar sites, which can potentially be

74 .001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the inc

75 Trigeminal neuralgia can occur in association with a range of other

76 s or open surgical procedures for trigeminal neuralgia can result in corneal anesthesia, neurotrophic

77 ion (FDA)-approved medication for trigeminal neuralgia carries substantial side effects, with many pa

78 dicine and found it effective for trigeminal neuralgia (category A) and probably effective in temporo

79 ly) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of

80 reating diabetic neuropathy and postherpetic neuralgia compared with placebo, gabapentin and pregabal

81 incidence of herpes zoster and postherpetic neuralgia consultations.

82 tion, Percutaneous Cryoablation, Intercostal Neuralgia, Cryosurgery, Ablation Techniques, Percutaneou

83 TNF, via TNFR1, mediates herpetic neuralgia development through downregulation of the inwa

84 al trials for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, generalized a

85 umothorax, and 3% risk of severe intercostal neuralgia due to nontarget ethanol deposition.

86 io 0.65 [95% 0.60-0.72]) and of postherpetic neuralgia fell by 50% (0.50 [0.38-0.67]).

87 were aged 18-90 years, had had postherpetic neuralgia for at least 6 months, and had an average base

88 al option for management of their trigeminal neuralgia for many years.

89 iew of surgical interventions for trigeminal neuralgia found not a single trial of what is becoming t

90 The group with postherpetic neuralgia had a mean density of 339 +/- 97 neurites/mm2

91 overlap between SUNCT, SUNA, and trigeminal neuralgia has challenged this traditional view.

92 ss in preventing herpes zoster, postherpetic neuralgia, herpes zoster ophthalmicus, and admission to

93 Trigeminal neuralgia, historically dubbed the "suicide disease," is

94 icacy of BIIB074 in patients with trigeminal neuralgia in a phase 2a study.

95 ation of BIIB074 in patients with trigeminal neuralgia in future clinical trials.

96 postherpetic neuralgia and chronic occipital neuralgia in humans.

97 treatment of herpes zoster and postherpetic neuralgia in immunocompetent older adults are reviewed,

98 in preventing herpes zoster and postherpetic neuralgia in immunocompetent older adults.

99 onsible for the spontaneous remission of the neuralgia in some patients.

100 incidence of herpes zoster and postherpetic neuralgia in this population.

101 Other causes of trigeminal neuralgia in which demyelination is involved or implicat

102 Theories of neuralgia included a constitutional predisposition and a

103 d severity of herpes zoster and postherpetic neuralgia increase with age in association with a progre

104 ccessing the foramen ovale during trigeminal neuralgia interventions.

105 ities available for patients with trigeminal neuralgia intolerable or resistant to medical therapy.

106 Trigeminal Neuralgia is a disorder that is characterized with elect

107 Trigeminal neuralgia is a very painful neurological condition with

108 Postherpetic neuralgia is not prevented by early systemic antivirals

109 ontrol.SIGNIFICANCE STATEMENT Acute herpetic neuralgia is the most important symptom of herpes zoster

110 Herpetic neuralgia is the most important symptom of herpes zoster

111 Current standard of care for trigeminal neuralgia is treatment with the sodium channel blockers

112 e is now persuasive evidence that trigeminal neuralgia is usually caused by demyelination of trigemin

113 ted in the painful condition of postherpetic neuralgia, is regulated by the cytoplasmic domains of gB

114 cause chronic neuropathic pain (postherpetic neuralgia) long after skin lesions heal.

115 rug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders wh

116 er, which may be complicated by postherpetic neuralgia, myelitis, meningoencephalitis, and VZV vascul

117 s was strongest for SMRs used for trigeminal neuralgia, neck pain, and painful cramps; evidence sugge

118 -89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, and Sept 30, 20

119 atients (aged 22-89 years) with postherpetic neuralgia of at least 6 months' duration from 29 centres

120 Patients with postherpetic neuralgia often have an increased sensitivity to a tacti

121 (PH), hemicrania continua (HC) and occipital neuralgia (ON), thereby bridging the gap between differe

122 eripheral nervous system (e.g. post-herpetic neuralgia or diabetic neuropathy) or to the central nerv

123 y for arteriovenous malformation, trigeminal neuralgia, or benign intracranial tumours, which include

124 al manifestations and etiology of trigeminal neuralgia, outline the neuro-ophthalmic features of trig

125 Thus, the pathophysiology of postherpetic neuralgia pain may involve a new bilateral mechanism.

126 A postherpetic-neuralgia patient abruptly discontinued pregabalin.

127 Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adu

128 tions of current treatments for postherpetic neuralgia (PHN) have led to the investigation of localis

129 Postherpetic neuralgia (PHN) is a common complication of shingles tha

130 Postherpetic neuralgia (PHN) is a syndrome of often intractable neuro

131 Post-herpetic neuralgia (PHN) is the most significant complication of

132 that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occu

133 ferences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters.

134 the incidence rates of HZ and post-herpetic neuralgia (PHN) since their introduction.

135 n the incidence rates of HZ and postherpetic neuralgia (PHN) since their introduction.

136 e the role of the microbiota in postherpetic neuralgia (PHN), a chronic pain condition resulting from

137 al reactivation are at risk for postherpetic neuralgia (PHN), a painful and long-lasting complication

138 burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for t

139 ted with herpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommending the HZ vacc

140 During postherpetic neuralgia (PHN), the cerebral spinal fluid (CSF) possess

141 often debilitating pain called postherpetic neuralgia (PHN), which can last for months after the dis

142 loping the painful condition of postherpetic neuralgia (PHN), which has been difficult to treat becau

143 ir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting af

144 prevent herpes zoster (HZ) and postherpetic neuralgia (PHN).

145 tributable risk and the risk of postherpetic neuralgia (PHN).

146 ding ophthalmic zoster (OZ) and postherpetic neuralgia (PHN).

147 S. adults, many of whom develop postherpetic neuralgia (PHN).

148 serious consequences, notably post-herpetic neuralgia (PHN).

149 e to acute and chronic pain, or postherpetic neuralgia (PHN).

150 of zoster (group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group

151 t patients with vessel-associated trigeminal neuralgia, probably because the resulting separation of

152 s aged 18-80 years with confirmed trigeminal neuralgia received open-label, BIIB074 150 mg three time

153 ded peripheral visual field loss, trigeminal neuralgia, recurrent Bell's palsy, and pulsatile tinnitu

154 idence on whether SUNCT, SUNA and trigeminal neuralgia should be considered separate entities or vari

155 icates a therapeutic overlap with trigeminal neuralgia, suggesting that sodium channels dysfunction m

156 ade has offered new insights into trigeminal neuralgia symptomatology, pathophysiology, and treatment

157 nerve root (FLIT) model of human trigeminal neuralgia that has improved face, construct, and predict

158 cohort of patients with classical trigeminal neuralgia, the prevalence and severity of neurovascular

159 al factor between SUNCT, SUNA and trigeminal neuralgia thereby further expanding the overlap between

160 in turn mediates the development of herpetic neuralgia through downregulation of the inwardly rectify

161 eral surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most repor

162 Trigeminal neuralgia (TN) is a facial pain disorder characterized b

163 Trigeminal neuralgia (TN) is a unique pain disorder characterized b

164 ly associate lesion formation and trigeminal neuralgia (TN) symptom onset in MS.

165 However little is known about how trigeminal neuralgia (TN), a condition in which trigeminal stimulat

166 lia that account for the genesis of herpetic neuralgia using a murine model of Herpes Simplex Virus T

167 Against postherpetic neuralgia, vaccine effectiveness waned from 83% (78% to

168 e vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4-81.8).

169 t diagnosis with treatment, and postherpetic neuralgia was identified using a validated algorithm.

170 confirmed intractable unilateral trigeminal neuralgia were measured before treatment with gamma knif

171 safe and effective treatment for trigeminal neuralgia, with a high rate of long-term success.

172 treatment with carbamazepine for trigeminal neuralgia, with modest improvement of symptoms.